Comparison of Cyproterone Acetate and Danazol in the Treatment of Pelvic Pain Associated With Endometriosis

Luigi Fedele, Fedele L, L Fedele, Luca Arcaini, L Arcaini, Arcaini L, Bianchi S, Stefano Bianchi, S Bianchi, A. Baglioni, Baglioni A, P Vercellini, Paolo Vercellini, Vercellini P
Obstetrics and gynecology · 1989 · vol. 73(6) , pp. 1000–1004 · doi:10.1097/00006250-198906000-00019 · PMID:2524684 · W1559741595
article OA: closed CC0 ⤵ 49 in-corpus citations
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-06 ⓘ

Cyproterone acetate and danazol both induced partial regression of endometriosis and relieved pelvic pain, but symptoms recurred in most patients after treatment withdrawal.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Twenty-three patients with laparoscopically diagnosed endometriosis and pelvic pain were allocated randomly to treatment with cyproterone acetate 27 mg plus ethinyl estradiol 0.035 mg/day (11 patients) or danazol 600 mg/day (12 patients). All women received treatment for 6 months, except for one in the cyproterone group who suspended treatment for nonmedical reasons and was excluded from analysis of the results. The clinical condition and pain symptoms were monitored in all patients for 1 year after treatment suspension. The intensity of pelvic pain at diagnosis, during treatment, and at follow-up was evaluated by a multidimensional verbal score and an analogue scale. At the end of treatment, a repeat laparoscopy was performed in those patients who agreed (four in the cyproterone group, five in the danazol group); the results showed a partial regression of endometriotic lesions in both groups, with no significant differences between them. Dysmenorrhea disappeared in all patients during treatment. At 6 months after suspension, dysmenorrhea recurred in 66% of the cyproterone group and 58% of the danazol group, and at 1 year in 89 and 92%, respectively. Intermenstrual pelvic pain improved markedly during treatment in both groups; 6 months after treatment withdrawal it was present in four cyproterone subjects and four danazol group patients, whereas after 1 year, only one woman in the danazol group did not have this symptom. Deep dyspareunia was less affected by treatment, and 6 months later had recurred in all the women.(ABSTRACT TRUNCATED AT 250 WORDS)
Full text 2,054 characters · extracted from oa-doi-fallback · click to expand
Comparison of Cyproterone Acetate and Danazol in the Treatment of Pelvic Pain Associated With Endometriosis - L. FEDELE - L. ARCAINI - S. BIANCHI - A. BAGLIONI - P. VERCELLINI Twenty-three patients with laparoscopically diagnosed endometriosis and pelvic pain were allocated randomly to treatment with cyproterone acetate 27 mg plus ethinyl estradiol 0.035 mg/day (11 patients) or danazol 600 mg/day (12 patients). All women received treatment for 6 months, except for one in the cyproterone group who suspended treatment for nonmedical reasons and was excluded from analysis of the results. The clinical condition and pain symptoms were monitored in all patients for 1 year after treatment suspension. The intensity of pelvic pain at diagnosis, during treatment, and at follow-up was evaluated by a multidimensional verbal score and an analogue scale. At the end of treatment, a repeat laparoscopy was performed in those patients who agreed (four in the cyproterone group, five in the danazol group); the results showed a partial regression of endometriotic lesions in both groups, with no significant differences between them. Dysmenorrhea disappeared in all patients during treatment. At 6 months after suspension, dysmenorrhea recurred in 66% of the cyproterone group and 58% of the danazol group, and at 1 year in 89 and 92%, respectively. Intermenstrual pelvic pain improved markedly during treatment in both groups; 6 months after treatment withdrawal it was present in four cyproterone subjects and four danazol group patients, whereas after 1 year, only one woman in the danazol group did not have this symptom. Deep dyspareunia was less affected by treatment, and 6 months later had recurred in all the women. A more marked antigonadotropic action was observed with cyproterone acetate and ethinyl estradiol, and this combination could play a useful role in the short-term medical treatment of pelvic pain associated with endometriosis, especially when it is appropriate to avoid the androgenic effects of danazol.(Obstet Gynecol 73:1000, 1989)

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisdysmenorrheadyspareunia

MeSH descriptors

Androgen Antagonists Cyproterone Danazol Endometriosis Pain Pelvic Neoplasms Pregnadienes Adult Androgen Antagonists Cyproterone Cyproterone Cyproterone Acetate Danazol Endometriosis Ethinyl Estradiol Ethinyl Estradiol Female Humans Pain Pain

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (46)

Source provenance

europepmc
last seen: 2026-08-13T06:15:24.848197+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:10.744835+00:00
unpaywall
last seen: 2026-08-13T06:47:16.638238+00:00
License: CC0 · commercial use OK